These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10160492)

  • 1. Socioeconomics of influenza and influenza vaccination in Europe.
    Nicholson KG
    Pharmacoeconomics; 1996; 9 Suppl 3():75-8. PubMed ID: 10160492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and effectiveness of influenza vaccination: a systematic review.
    D'Angiolella LS; Lafranconi A; Cortesi PA; Rota S; Cesana G; Mantovani LG
    Ann Ist Super Sanita; 2018; 54(1):49-57. PubMed ID: 29616674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of influenza vaccination. Assessment for The Netherlands.
    Postma MJ; Bos JM; van Gennep M; Jager JC; Baltussen R; Sprenger MJ
    Pharmacoeconomics; 1999; 16 Suppl 1():33-40. PubMed ID: 10623374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of healthy children against seasonal influenza: a European perspective.
    Heikkinen T; Tsolia M; Finn A
    Pediatr Infect Dis J; 2013 Aug; 32(8):881-8. PubMed ID: 23856713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of a Television Campaign to Promote Seasonal Influenza Vaccination Among the Elderly.
    Kim M; Yoo BK
    Value Health; 2015 Jul; 18(5):622-30. PubMed ID: 26297090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of cost-benefit analyses of influenza vaccine.
    Perez-Tirse J; Gross PA
    Pharmacoeconomics; 1992 Sep; 2(3):198-206. PubMed ID: 10147010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential economic value of influenza vaccination for healthcare workers in The Netherlands.
    Meijboom MJ; Riphagen-Dalhuisen J; Hak E
    Influenza Other Respir Viruses; 2018 Jul; 12(4):457-464. PubMed ID: 29624882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
    Postma MJ; Jansema P; van Genugten ML; Heijnen ML; Jager JC; de Jong-van den Berg LT
    Drugs; 2002; 62(7):1013-24. PubMed ID: 11985488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza cost and cost-effectiveness studies globally--a review.
    Peasah SK; Azziz-Baumgartner E; Breese J; Meltzer MI; Widdowson MA
    Vaccine; 2013 Nov; 31(46):5339-48. PubMed ID: 24055351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of childhood influenza vaccination in Europe: results from a systematic review.
    Boccalini S; Bechini A; Moscadelli A; Paoli S; Schirripa A; Bonanni P
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):911-922. PubMed ID: 33930994
    [No Abstract]   [Full Text] [Related]  

  • 14. French economic evaluations of influenza and influenza vaccination.
    Levy E
    Pharmacoeconomics; 1996; 9 Suppl 3():62-6. PubMed ID: 10160489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic review].
    Valcárcel Nazco C; García Lorenzo B; Del Pino Sedeño T; García Pérez L; Brito García N; Linertová R; Ferrer Rodríguez J; Imaz Iglesia I; Serrano Aguilar P
    Rev Esp Salud Publica; 2018 Oct; 92():. PubMed ID: 30327454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required.
    Newall AT; Dehollain JP
    Vaccine; 2014 Mar; 32(12):1323-5. PubMed ID: 24486359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.